Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma
Reinhard Dummer(University Hospital of Zurich), Keith T. Flaherty(Cancer Research Center), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Jan Willem B. de Groot(Isala), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Laure A. De Parseval(Novartis (Switzerland)), Michael D. Pickard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Carola Berking(Universitätsklinikum Erlangen), Carmen Loquai(Johannes Gutenberg University Mainz), Helen Gogas(National and Kapodistrian University of Athens), Ivana Krajsovy, Caroline Robert(Institut Gustave Roussy), Claus Garbe(University of Tübingen), Victor Sandor(Peter MacCallum Cancer Centre), Naoya Yamazaki(Tokyo National Hospital)
Journal Der Deutschen Dermatologischen Gesellschaft
January 1, 2017
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k